[
  {
    "ts": null,
    "headline": "Top Analyst Reports for Microsoft, Amazon.com & Johnson & Johnson",
    "summary": "Microsoft rides AI and cloud growth, Amazon leans on AWS and Prime, and Johnson & Johnson gains from strong pharma momentum despite patent risks.",
    "url": "https://finnhub.io/api/news?id=c22176a4e79964249f5be31b1a62a574487e75e93b8db41971189a324270a29a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759784820,
      "headline": "Top Analyst Reports for Microsoft, Amazon.com & Johnson & Johnson",
      "id": 136998873,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Microsoft rides AI and cloud growth, Amazon leans on AWS and Prime, and Johnson & Johnson gains from strong pharma momentum despite patent risks.",
      "url": "https://finnhub.io/api/news?id=c22176a4e79964249f5be31b1a62a574487e75e93b8db41971189a324270a29a"
    }
  },
  {
    "ts": null,
    "headline": "Bernstein Maintains Johnson & Johnson (JNJ) Market Perform Recommendation",
    "summary": "Bernstein Maintains Johnson & Johnson (JNJ) Market Perform Recommendation",
    "url": "https://finnhub.io/api/news?id=b85ddf9e7506baa415306d8de57d6d6b2243923750d826f48d0191b6a81582a0",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759779530,
      "headline": "Bernstein Maintains Johnson & Johnson (JNJ) Market Perform Recommendation",
      "id": 136988924,
      "image": "",
      "related": "JNJ",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b85ddf9e7506baa415306d8de57d6d6b2243923750d826f48d0191b6a81582a0"
    }
  },
  {
    "ts": null,
    "headline": "Earnings Are Coming. Wall Street Hopes Strong Profits Can Keep the Market Rally Going.",
    "summary": "Third-quarter profit growth should be solid. Tech and AI will lead the way, but earnings momentum could broaden too.",
    "url": "https://finnhub.io/api/news?id=309a544838bb1c11a4b759cca0698a2c912510216becc69cfe7ee748d9cb94ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759772580,
      "headline": "Earnings Are Coming. Wall Street Hopes Strong Profits Can Keep the Market Rally Going.",
      "id": 136989037,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Third-quarter profit growth should be solid. Tech and AI will lead the way, but earnings momentum could broaden too.",
      "url": "https://finnhub.io/api/news?id=309a544838bb1c11a4b759cca0698a2c912510216becc69cfe7ee748d9cb94ca"
    }
  },
  {
    "ts": null,
    "headline": "Diffuse Cutaneous Systemic Sclerosis Market Forecast: Opportunities and Growth Trends Upto 2034 | DelveInsight",
    "summary": "The diffuse cutaneous systemic sclerosis market landscape is evolving from conventional symptom-focused strategies toward therapies that specifically target fibrosis and immune modulation, addressing a significant unmet need. The development pipeline is varied, with prominent candidates including Mitsubishi Tanabe Pharma’s MT-7117, Cumberland’s ifetroban, Johnson & Johnson’s guselkumab, and Kyverna’s KYV-101. The dcSSc market is anticipated to move toward earlier intervention with targeted thera",
    "url": "https://finnhub.io/api/news?id=3a96d673fad800ab7302636a8b19c3c5b521809503cde1f57b653700adb5158f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759770000,
      "headline": "Diffuse Cutaneous Systemic Sclerosis Market Forecast: Opportunities and Growth Trends Upto 2034 | DelveInsight",
      "id": 136989207,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The diffuse cutaneous systemic sclerosis market landscape is evolving from conventional symptom-focused strategies toward therapies that specifically target fibrosis and immune modulation, addressing a significant unmet need. The development pipeline is varied, with prominent candidates including Mitsubishi Tanabe Pharma’s MT-7117, Cumberland’s ifetroban, Johnson & Johnson’s guselkumab, and Kyverna’s KYV-101. The dcSSc market is anticipated to move toward earlier intervention with targeted thera",
      "url": "https://finnhub.io/api/news?id=3a96d673fad800ab7302636a8b19c3c5b521809503cde1f57b653700adb5158f"
    }
  },
  {
    "ts": null,
    "headline": "My Top 5 Biotech Stocks Big Pharma Could Buy Next",
    "summary": "Many of the biotech stocks remain outside of Mr. Market's interest zone. Check out five biotech firms that may be of interest to Big Pharma players.",
    "url": "https://finnhub.io/api/news?id=0615cc217ad0cd350a198a8133c50199b31af463e4f96ab378a062934e7cccc8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759757340,
      "headline": "My Top 5 Biotech Stocks Big Pharma Could Buy Next",
      "id": 136988239,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1146642361/image_1146642361.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Many of the biotech stocks remain outside of Mr. Market's interest zone. Check out five biotech firms that may be of interest to Big Pharma players.",
      "url": "https://finnhub.io/api/news?id=0615cc217ad0cd350a198a8133c50199b31af463e4f96ab378a062934e7cccc8"
    }
  },
  {
    "ts": null,
    "headline": "How J&J's Innovative Medicines Segment is Poised Ahead of Q3 Results",
    "summary": "JNJ's Innovative Medicine sales face biosimilar pressure and IRA headwinds, but growth drivers like Darzalex, Tremfya and Erleada may have ensured steady Q3 momentum.",
    "url": "https://finnhub.io/api/news?id=f3f2086007ac91191096aa6bdac656413082b1bbea04982fe6d38045151d30d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759753920,
      "headline": "How J&J's Innovative Medicines Segment is Poised Ahead of Q3 Results",
      "id": 136989208,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ's Innovative Medicine sales face biosimilar pressure and IRA headwinds, but growth drivers like Darzalex, Tremfya and Erleada may have ensured steady Q3 momentum.",
      "url": "https://finnhub.io/api/news?id=f3f2086007ac91191096aa6bdac656413082b1bbea04982fe6d38045151d30d0"
    }
  },
  {
    "ts": null,
    "headline": "Did U.S. Orthopaedic Partners’ Medtech Deal Just Shift Johnson & Johnson’s (JNJ) Investment Narrative?",
    "summary": "In the past week, U.S. Orthopaedic Partners announced a collaboration with Johnson & Johnson, selecting the medtech company as its official vendor for total joint products across its clinical platform after a surgeon-led evaluation of product performance and durability. This agreement not only grants USOP access to advanced solutions such as the VELYS Robotic-Assisted Solution but also highlights a growing industry trend where physician-led management organizations collaborate closely with...",
    "url": "https://finnhub.io/api/news?id=2112ee75f7868432b35c219074b9c66f990594e98c6e49b2a261d631c3e5ff5a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759753225,
      "headline": "Did U.S. Orthopaedic Partners’ Medtech Deal Just Shift Johnson & Johnson’s (JNJ) Investment Narrative?",
      "id": 136989209,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "In the past week, U.S. Orthopaedic Partners announced a collaboration with Johnson & Johnson, selecting the medtech company as its official vendor for total joint products across its clinical platform after a surgeon-led evaluation of product performance and durability. This agreement not only grants USOP access to advanced solutions such as the VELYS Robotic-Assisted Solution but also highlights a growing industry trend where physician-led management organizations collaborate closely with...",
      "url": "https://finnhub.io/api/news?id=2112ee75f7868432b35c219074b9c66f990594e98c6e49b2a261d631c3e5ff5a"
    }
  },
  {
    "ts": null,
    "headline": "Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus",
    "summary": "Amneal Pharmaceuticals, Leidos and Vishay Precision stand out as Zacks highlights amid market volatility and shifting rate expectations.",
    "url": "https://finnhub.io/api/news?id=7ae2dc27719767dccba5f3a04033e4074b3333381eee55b8b4358ec0548ec146",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759752420,
      "headline": "Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus",
      "id": 136989210,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Amneal Pharmaceuticals, Leidos and Vishay Precision stand out as Zacks highlights amid market volatility and shifting rate expectations.",
      "url": "https://finnhub.io/api/news?id=7ae2dc27719767dccba5f3a04033e4074b3333381eee55b8b4358ec0548ec146"
    }
  },
  {
    "ts": null,
    "headline": "Basil Systems Launches Safety Signaling Solution to Proactively Detect and Prevent Medical Device Risks",
    "summary": "BOSTON, October 06, 2025--Basil Systems Launches Safety Signaling Solution to Proactively Detect and Prevent Medical Device Risks",
    "url": "https://finnhub.io/api/news?id=0472eea644745fd6c0c06574245455434f901e3d50001b47f72afcbfaddeaaf0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759752000,
      "headline": "Basil Systems Launches Safety Signaling Solution to Proactively Detect and Prevent Medical Device Risks",
      "id": 136989212,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "BOSTON, October 06, 2025--Basil Systems Launches Safety Signaling Solution to Proactively Detect and Prevent Medical Device Risks",
      "url": "https://finnhub.io/api/news?id=0472eea644745fd6c0c06574245455434f901e3d50001b47f72afcbfaddeaaf0"
    }
  }
]